Clinical Trials Directory
We are doing this study to find the most effective, safe dose of an experimental drug called NX-5948 (the study drug). We want to know how well this study drug works in people with B-cell lymphomas.
We are doing this study to find the most effective, safe dose of an experimental drug called NVL-655 (the study drug). We want to know how well the study drug works compared to alectinib, which is a standard treatment for NSCLC.
This study has three parts, called screening, treatment, and follow up. During screening, doctors will check if a person can join the study. If eligible, participants will take a study medicine called NX 5948 by mouth once every day. The medicine is taken in cycles that last 28 days. People will keep taking the medicine as long as it is helping and side effects are manageable. Treatment may stop if the cancer gets worse, side effects become too severe, or the study ends. After treatment stops, participants will continue to be followed by the study team so doctors can check their health over time.
We are doing this study to find out which type of surgery has the best outcomes for people who have shoulder dislocations with bone loss. There are 3 types of surgeries that doctors can perform to stabilize the shoulder of people who have this type of injury, but there is no evidence at this time that proves one is better than the others. We hope this study can help us figure out how to choose the best option for different patients. This is an observational study and participation will not affect the treatment option you choose to pursue.
In this study, people will visit the clinic about every twelve weeks for checkups, lab tests, and other health exams. At each visit, they will receive a shot under the skin. The shot will either contain the study medicine, called olpasiran, or a placebo, which is a shot with no medicine in it. Participants are placed into one of these two groups by chance, like flipping a coin, and neither the doctor nor the participant will know which one they are getting. The study will last for several years. During this time, the team will check blood tests, look at heart health, and watch for any side effects. The main goal is to learn if olpasiran can safely lower Lp(a) levels and help prevent serious heart problems in the future.
People in this study may get a donor heart that is kept safe using a special system called the OCS Heart System, or they may get a heart kept cold in the usual way. Which one they get depends on the heart they are matched with. After the transplant, the study will collect information from their medical records for six months.
In this study, you will be placed into one of two groups by chance. One group will have donated lungs preserved using a special system called the OCS Lung System with a new solution. The other group will have the lungs preserved using the usual cold storage method. You will be followed from the time you agree to join the study until thirty days later or until you leave the hospital, whichever is longer. The study does not require any extra tests or visits. The study team will collect information from your medical records based on the care, tests, and procedures you already receive.
People in this study will be put into different groups by chance, like picking straws. The groups will get different treatments: - Some will get a medicine called ONL1204 in small or larger amounts every 12 or 24 weeks. - Some will get pretend shots (called sham injections) every 12 or 24 weeks. - Some will get a different medicine called avacincaptad pegol about once every 28 days. There is a little more than a 50% chance of getting ONL1204, about an 18% chance of getting the pretend shots, and about a 27% chance of getting avacincaptad pegol. The study will last about 76 weeks. During that time, people will need to visit the clinic at least 8 times. They will have tests and check-ups that are part of regular care and also for the study.